Korro Bio (KRRO) Accumulated Expenses (2018 - 2026)
Korro Bio's (KRRO) quarterly Accumulated Expenses came in at $1.3 million in Q1 2026, down 63.24% YoY from $3.6 million in Q1 2025, and down 27.36% on a QoQ basis from $1.8 million in Q4 2025.
Korro Bio (KRRO) Accumulated Expenses (2018 - 2026) Analysis & Trends
Korro Bio (KRRO) has 9 years of Accumulated Expenses data on file, last reported at $1.3 million in Q1 2026.
- Quarterly Accumulated Expenses fell 63.24% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (down 63.24% YoY) and the FY2025 annual result came in at $1.8 million, down 50.01% from the prior year.
- Accumulated Expenses slipped to $1.3 million in Q1 2026, from $1.8 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $10.2 million in Q4 2023 to a low of $1.3 million in Q1 2026.
- A 5-year average of $4.4 million and a median of $4.9 million in 2023 frame the typical range for Accumulated Expenses.
- The widest YoY moves for Accumulated Expenses: up 221.64% in 2023, down 65.52% in 2023.
- Tracing KRRO's Accumulated Expenses over 5 years: stood at $3.2 million in 2022, then jumped by 221.64% to $10.2 million in 2023, then sank by 63.84% to $3.7 million in 2024, then tumbled by 50.01% to $1.8 million in 2025, then dropped by 27.36% to $1.3 million in 2026.
- The last three Accumulated Expenses figures came in at $1.3 million (Q1 2026), $1.8 million (Q4 2025), and $5.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Korro Bio | 231.77 Mn | 116.73 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.07 Mn |
| Mar 31, 2026 | 1.34 Mn |
| Dec 31, 2025 | 1.85 Mn |
| Sep 30, 2025 | 5.86 Mn |
| Jun 30, 2025 | 5.66 Mn |
| Mar 31, 2025 | 3.65 Mn |
| Dec 31, 2024 | 3.69 Mn |
| Sep 30, 2024 | 3.06 Mn |
| Jun 30, 2024 | 6.18 Mn |
| Mar 31, 2024 | 5.16 Mn |
| Dec 31, 2023 | 10.21 Mn |
| Sep 30, 2023 | 1.87 Mn |
| Jun 30, 2023 | 4.87 Mn |
| Mar 31, 2023 | 5.57 Mn |
| Dec 31, 2022 | 3.18 Mn |
| Sep 30, 2022 | 5.42 Mn |
| Jun 30, 2022 | 5.50 Mn |
| Mar 31, 2022 | 2.15 Mn |
| Dec 31, 2021 | 4.38 Mn |
| Sep 30, 2021 | 3.52 Mn |